Last reviewed · How we verify
NSAID's
NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Mild to moderate pain, Fever, Inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis).
At a glance
| Generic name | NSAID's |
|---|---|
| Also known as | Diclophenac Potassium |
| Sponsor | Saglik Bilimleri Universitesi Gulhane Tip Fakultesi |
| Drug class | Non-steroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Pain management, Inflammation, Rheumatology |
| Phase | FDA-approved |
Mechanism of action
NSAIDs block COX-1 and/or COX-2 enzymes, which catalyze the conversion of arachidonic acid to prostaglandins and thromboxanes. By reducing prostaglandin levels, NSAIDs suppress inflammatory mediators, reduce pain signaling, and lower fever set points. Different NSAIDs vary in their selectivity for COX-1 versus COX-2, affecting their efficacy and side effect profiles.
Approved indications
- Mild to moderate pain
- Fever
- Inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis)
- Dysmenorrhea
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Renal impairment
- Cardiovascular events (myocardial infarction, stroke)
- Hypersensitivity reactions
Key clinical trials
- The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF (PHASE3)
- Verifying the Effectiveness of the NUsurface® System (NA)
- The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System) (NA)
- The Standard Care Versus Celecoxib Outcome Trial (PHASE4)
- Pharmacological Prophylaxis of Post- Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis (PHASE4)
- The Effect of Kinesio Taping Application for Dysmenorrhea (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NSAID's CI brief — competitive landscape report
- NSAID's updates RSS · CI watch RSS
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi portfolio CI